Methods of treating anemia by inhibition of vascular endothelial growth factor (VEGF)
First Claim
1. A method of treating an anemic disorder in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist capable of blocking, inhibiting, or ameliorating VEGF-mediated activity, wherein the VEGF antagonist is fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4).
1 Assignment
0 Petitions
Accused Products
Abstract
Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia, increasing hematocrit levels, and increasing or stimulating erythropoietin, particularly in subjects being treated for cancer with chemotherapeutic agents and/or radiation.
-
Citations
12 Claims
-
1. A method of treating an anemic disorder in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist capable of blocking, inhibiting, or ameliorating VEGF-mediated activity, wherein the VEGF antagonist is fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4). - View Dependent Claims (2, 3, 4, 5, 6)
- C1(a) (SEQ ID NO;
-
7. A method of treating anemia expected to result from cancer treatment in a human subject at risk, comprising administering to the human subject fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4). - View Dependent Claims (8)
- C1(a) (SEQ ID NO;
-
9. A method of increasing hematocrit level in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4). - View Dependent Claims (10)
- C1(a) (SEQ ID NO;
-
11. A method of increasing erythropoietin levels in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4).
- C1(a) (SEQ ID NO;
-
12. A method of stimulating erythropoiesis in a human subject in need thereof, comprising administering to the human subject a vascular endothelial growth factor (VEGF) antagonist comprising fusion polypeptide VEGRF1R2-FcΔ
- C1(a) (SEQ ID NO;
4).
- C1(a) (SEQ ID NO;
Specification